← back to search

Ying‐Hong Shi

Cancer Institute (WIA) · ET
🔎 Find collaborators in Hepatology · Surgery →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Hepatology · Surgery
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Cholangiocarcinoma and Gallbladder Cancer Studies, Autophagy in Disease and Therapy, and Ferroptosis and cancer prognosis.
h-index
57
citations
16,296
works
336
NIH funding
primary concept
Medicine
email

Recent publications

DNMT2-m5C-ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation-Mediated Notch Pathway.
2026cited by 0position: contributordoi
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
˜The œLancet. Gastroenterology & hepatology 2025cited by 35position: firstdoi
Metabolism archetype cancer cells induce protumor TREM2+ macrophages via oxLDL-mediated metabolic interplay in hepatocellular carcinoma
Nature Communications 2025cited by 23position: lastdoi
Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8+T and tumor cells
Signal Transduction and Targeted Therapy 2025cited by 15position: middledoi
Metabolism archetype cancer cells induce protumor TREM2<sup>+</sup> macrophages via oxLDL-mediated metabolic interplay in hepatocellular carcinoma.
2025cited by 11position: contributordoi
Targeting Deltex E3 Ubiquitin Ligase 2 Inhibits Tumor-associated Neutrophils and Sensitizes Hepatocellular Carcinoma Cells to Immunotherapy.
2025cited by 9position: contributordoi
Lysine‐specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti‐programmed death 1 therapy in liver cancer
Clinical and Translational Medicine 2025cited by 6position: middledoi
Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial
˜The œLancet. Gastroenterology & hepatology 2025cited by 4position: middledoi
Predictive value of neutrophil-to-lymphocyte ratio in recurrent HCC after repeat hepatectomy or salvage liver transplantation.
2025cited by 4position: contributordoi
Targeting HMGB2 acts as dual immunomodulator by bolstering CD8<sup>+</sup> T cell function and inhibiting tumor growth in hepatocellular carcinoma.
2025cited by 3position: contributordoi
Targeting CREB3L2-mediated lipid metabolism overcomes lenvatinib resistance and attenuates the progression of hepatocellular carcinoma.
2025cited by 0position: contributordoi
CD8+ T cell-based cancer immunotherapy
Journal of Translational Medicine 2024cited by 85position: middledoi
Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma
Nature Communications 2024cited by 43position: middledoi
Cancer-associated fibroblasts contributed to hepatocellular carcinoma recurrence and metastasis via CD36-mediated fatty-acid metabolic reprogramming
Experimental Cell Research 2024cited by 37position: lastdoi
Natural killer cell-based cancer immunotherapy: from basics to clinical trials
Experimental Hematology and Oncology 2024cited by 28position: firstdoi
Inhibition of SIRT1 relieves hepatocarcinogenesis via alleviating autophagy and inflammation
International Journal of Biological Macromolecules 2024cited by 20position: middledoi
Targeting Deltex E3 Ubiquitin Ligase 2 Inhibits Tumor‐associated Neutrophils and Sensitizes Hepatocellular Carcinoma Cells to Immunotherapy
Advanced Science 2024cited by 9position: lastdoi
Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis.
2024cited by 1position: contributordoi
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Liver Cancer 2023cited by 435position: middledoi
CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor
Cell Discovery 2023cited by 305position: lastdoi
Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack.
2023cited by 105position: contributordoi
Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma
Cancer Cell 2023cited by 100position: middledoi
Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation
Hepatology International 2023cited by 55position: lastdoi
A RIPK3-independent role of MLKL in suppressing parthanatos promotes immune evasion in hepatocellular carcinoma
Cell Discovery 2023cited by 50position: lastdoi
Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation.
2023cited by 41position: contributordoi
Methyltransferase like 3 inhibition limits intrahepatic cholangiocarcinoma metabolic reprogramming and potentiates the efficacy of chemotherapy
Oncogene 2023cited by 39position: lastdoi
Single-cell and spatial architecture of primary liver cancer
Communications Biology 2023cited by 34position: middledoi
Methyltransferase like 3 inhibition limits intrahepatic cholangiocarcinoma metabolic reprogramming and potentiates the efficacy of chemotherapy.
2023cited by 33position: contributordoi
Deciphering intratumoral heterogeneity of hepatocellular carcinoma with microvascular invasion with radiogenomic analysis
Journal of Translational Medicine 2023cited by 32position: middledoi
Laser-Induced Combinatorial Chemotherapeutic, Chemodynamic, and Photothermal Therapy for Hepatocellular Carcinoma Based on Oxaliplatin-Loaded Metal–Organic Frameworks
ACS Applied Materials & Interfaces 2023cited by 31position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jia Fan · China Medical University66 papers (2012–2025)Jian Zhou · Shenzhen University Health Science Center39 papers (2012–2023)Zhen‐Bin Ding · Bengbu Medical College28 papers (2012–2025)Jian Zhou · Ministry of Education of the People's Republic of China23 papers (2018–2025)Wei‐Ren Liu · Chung Yuan Christian University22 papers (2014–2025)Meng‐Xin Tian · Sun Yat-sen University21 papers (2014–2025) · 19 papers (2019–2026)Wei‐Feng Qu · Ministry of Education of the People's Republic of China19 papers (2019–2025)Zhi Dai · Fudan University19 papers (2012–2025)Zheng Tang · Ruijin Hospital17 papers (2017–2025)Shuang‐Jian Qiu · Sun Yat-sen University17 papers (2012–2025)Xi‐Fei Jiang · Sun Yat-sen University15 papers (2017–2024)Chenyang Tao · Guangzhou University of Chinese Medicine15 papers (2017–2025)Yuan‐Fei Peng · Fudan University14 papers (2012–2022)Ai‐Wu Ke · Fudan University14 papers (2013–2025)Qiang Gao · Northeastern University13 papers (2012–2025)Weiren Liu · Ministry of Education of the People's Republic of China12 papers (2018–2025)Run Huang · University of Southern California12 papers (2021–2025)Zheng‐Jun Zhou · Sun Yat-sen University11 papers (2012–2022)Guo‐Ming Shi · Sun Yat-sen University11 papers (2012–2023)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Hepatology · Surgery →